Results 91 to 100 of about 42,265 (195)

Levodopa Efficacy and GLP‐1 Receptor Agonists

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez   +3 more
wiley   +1 more source

Altered Cerebrospinal Fluid Tryptophan–Kynurenine Pathway Metabolism in Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background Alterations in tryptophan–kynurenine (TRP‐KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). Objective The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
Ryunosuke Nagao   +8 more
wiley   +1 more source

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. [PDF]

open access: yesNat Aging, 2023
Pereira JB   +9 more
europepmc   +1 more source

Unilateral Freezing of Gait in Normal Pressure Hydrocephalus after Stroke

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Jose Portales   +2 more
wiley   +1 more source

Natural Killer Subset Changes and Vascular Endothelial Growth Factor‐A Plasma Profile in Progressive Supranuclear Palsy: The NKscape Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Emerging evidence implicates neuroinflammation in progressive supranuclear palsy (PSP) pathophysiology, with elevated cyto‐chemokines suggesting natural killer (NK) cell involvement. Methods We characterized peripheral NK in PSP (N = 11) versus Parkinson's disease (PD, N = 10) and healthy controls (HC, N = 8) at both ...
Marina Picillo   +11 more
wiley   +1 more source

Large-scale activation likelihood estimation meta-analysis of parkinsonian disorders. [PDF]

open access: yesBrain Commun, 2023
Ellis EG   +6 more
europepmc   +1 more source

Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background Blood–brain barrier disruption is increasingly recognized in synucleinopathies, but the role of the endothelial glycocalyx (GLX) in Parkinson's disease (PD) and multiple system atrophy (MSA) remains unclear. Objectives The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to ...
Jonas Folke   +15 more
wiley   +1 more source

Detecting Abnormal Eye Movements in Patients with Neurodegenerative Diseases – Current Insights

open access: yesEye and Brain
Akila Sekar,1 Muriel TN Panouillères,2,3 Diego Kaski1 1SENSE Research Unit, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK; 2NeuroClues, Ottignies-Louvain-la-Neuve, Belgium; 3CIAMS, Université Paris-
Sekar A, Panouillères MT, Kaski D
doaj  

Macroscale Gradient‐Informed Neural Oscillation Topography in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is characterized by large‐scale disruptions in beta and gamma oscillations. Although subcortical beta power is an established biomarker for current adaptive deep brain stimulation (aDBS), it may not fully capture the global pathophysiological burden and the macroscale hierarchical reorganization of the ...
Hao Ding   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy